“Banking on a cure for all causes of late-life disabling cognitive impairments is like planning your retirement with lottery tickets: you may win, and win big, but odds are you’re not going to.” — Jason Karlawish, MD, of the Penn Memory Center at the University of Pennsylvania in Philadelphia, about what to expect from investigational Alzheimer’s treatments.
“Generally when patients develop CVST, the first thing you do is give them heparin. In this situation, that would be the worst thing to do.” — Rajiv Pruthi, MBBS, of the Mayo Clinic in Rochester, Minnesota, explaining that clinicians need to be prepared for the rare possibility of cerebral venous sinus thrombosis after COVID-19 vaccination.
“I didn’t immediately go from that experience to running for office, but I always felt that being a trauma surgeon was community service.” — Randall Friese, MD, an Arizona trauma surgeon, who was on duty when former Congresswoman Gabby Giffords (D-Ariz.) was shot, on his decision to run for Congress himself.
“The FDA did not say this before, but now they do.” — Jacqueline French, MD, of the NYU Comprehensive Epilepsy Center, about a new FDA warning that potential arrhythmia risks with the seizure and mental health drug lamotrigine (Lamictal) may be a class effect.
“Glaucoma is more than just a disease of eye pressure.” — Sean Mullany, MD, of Flinders University in Adelaide, Australia, on research showing cognitive impairment occurred more than twice as often in patients with normotensive compared with high-tension glaucoma.
“This will go a long way in helping us with widespread use.” — Lukasz Kwapisz, MD, of Baylor College of Medicine in Houston, discussing how dual biologic or small molecule therapy could benefit certain highly selected, refractory inflammatory bowel disease patients.